D-Index & Metrics Best Publications

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center
United States

Medicine

USA

2023

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 244 Citations 281,641 4,544 World Ranking 23 National Ranking 18

Best Scientists D-index 244 Citations 281,729 4,557 World Ranking 35 National Ranking 26

Research.com Recognitions

Awards & Achievements

2023 - Research.com Best Scientist Award

2023 - Research.com Medicine in United States Leader Award

2022 - Research.com Best Scientist Award

2012 - Fellow of the American Association for the Advancement of Science (AAAS)

Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study Hagop M. Kantarjian is best known for:

Chemotherapy
Cancer
Leukemia

His research on Chronic lymphocytic leukemia, Cytarabine and Chronic myelogenous leukemia is centered around Leukemia. He merges many fields, such as Chronic lymphocytic leukemia and Fludarabine, in his writings. He conducted interdisciplinary study in his works that combined Cytarabine and Chemotherapy. He conducts interdisciplinary study in the fields of Chemotherapy and Cyclophosphamide through his works. His multidisciplinary approach integrates Cyclophosphamide and Fludarabine in his work. The research on Nilotinib, Imatinib mesylate and Dasatinib is part of his Imatinib project. His Internal medicine study typically links adjacent topics like Clinical trial. He carries out multidisciplinary research, doing studies in Gastroenterology and Oncology. In his study, Hagop M. Kantarjian carries out multidisciplinary Oncology and Gastroenterology research.

His most cited work include:

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias (869 citations)
Long-Term Follow-Up of Patients With Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine Regimens as Initial Therapy (410 citations)
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate (357 citations)

What are the main themes of his work throughout his whole career to date

As part of his inquiry into Chronic myelogenous leukemia and Chronic lymphocytic leukemia, Hagop M. Kantarjian is doing Leukemia research. Hagop M. Kantarjian carries out multidisciplinary research, doing studies in Chronic lymphocytic leukemia and Leukemia. He integrates many fields, such as Imatinib and engineering, in his works. As part of his studies on Internal medicine, Hagop M. Kantarjian often connects relevant subjects like Adverse effect. Hagop M. Kantarjian undertakes interdisciplinary study in the fields of Oncology and Gastroenterology through his works. He undertakes interdisciplinary study in the fields of Gastroenterology and Oncology through his works. His work on Dasatinib expands to the thematically related Myeloid leukemia. By researching both Gene and Biochemistry, he produces research that crosses academic boundaries. He integrates Biochemistry and Gene in his studies.

Hagop M. Kantarjian most often published in these fields:

Internal medicine (89.19%)
Oncology (55.41%)
Gastroenterology (50.68%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng.
The New England Journal of Medicine (2001)

6582 Citations

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

Timothy J. Ley;Christopher Miller;Li Ding;Benjamin J. Raphael.
The New England Journal of Medicine (2013)

5334 Citations

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)

4398 Citations

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)

4139 Citations

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta.
The New England Journal of Medicine (2001)

3441 Citations

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Blood (2012)

2683 Citations

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot.
The New England Journal of Medicine (2002)

2611 Citations

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus.
Blood (2013)

2302 Citations

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato.
The New England Journal of Medicine (2006)

2074 Citations

A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover.
The New England Journal of Medicine (2003)

2071 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Hagop M. Kantarjian